In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA reform/PDUFA linkage endorsed by NDMA, Hutt tells annual meeting.

This article was originally published in The Tan Sheet

Executive Summary

PDUFA/FDA REFORM LINKAGE ENDORSED BY NDMA, Covington & Burling attorney Peter Hutt told association members at the Nonprescription Drug Manufacturers Association's May 15-18 annual meeting in White Sulphur Springs, W.Va. Speaking during NDMA's "Report from Washington" panel presentation, Hutt noted the association's continuing efforts to lobby for inclusion of national uniformity provisions, as well as reauthorization of user fees for Rx-to-OTC switch and original NDAed OTC drugs, in FDA-related legislation under discussion on Capitol Hill.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts